CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$46.74 USD
-1.44 (-2.99%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $46.75 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 |
Depreciation/Amortization & Depletion | 19.84 | 24.17 | 32.06 | 9.18 | 4.73 |
Net Change from Assets/Liabilities | -193.59 | 19.85 | 26.86 | 33.44 | -48.43 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 66.98 | 110.42 | 102.39 | 67.88 | 33.52 |
Net Cash From Operating Activities | -260.38 | -495.74 | 538.97 | -238.37 | 56.68 |
Property & Equipment | -9.47 | -37.19 | -81.71 | -18.36 | -6.68 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 386.62 | -221.47 | -953.73 | -522.81 | 0.00 |
Other Investing Activities | -2.50 | 0.00 | 0.00 | 0.00 | 8.01 |
Net Cash from Investing Activities | 374.65 | -258.66 | -1,035.43 | -541.17 | 1.33 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 62.66 | 38.59 | 250.95 | 1,016.15 | 430.98 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 62.66 | 38.59 | 250.95 | 1,016.15 | 430.98 |
Effect of Exchange Rate Changes | 0.07 | -0.08 | -0.01 | 0.04 | 0.02 |
Net Change In Cash & Equivalents | 177.01 | -715.88 | -245.52 | 236.66 | 489.00 |
Cash at Beginning of Period | 224.06 | 939.94 | 1,185.47 | 948.81 | 459.81 |
Cash at End of Period | 401.07 | 224.06 | 939.94 | 1,185.47 | 948.81 |
Diluted Net EPS | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -243.00 | -116.59 | -153.61 | -242.96 | -130.81 |
Depreciation/Amortization & Depletion | 9.68 | 4.83 | 19.84 | 14.94 | 10.01 |
Net Change from Assets/Liabilities | 220.98 | 210.49 | -193.59 | 10.39 | -42.17 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 26.51 | 11.02 | 66.98 | 53.33 | 38.52 |
Net Cash From Operating Activities | 14.17 | 109.75 | -260.38 | -164.30 | -124.45 |
Property & Equipment | -1.43 | -0.72 | -9.47 | -8.73 | -6.61 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -223.28 | -89.58 | 386.62 | 467.33 | 342.87 |
Other Investing Activities | 0.00 | -7.50 | -2.50 | -2.50 | -1.50 |
Net Cash from Investing Activities | -224.71 | -97.80 | 374.65 | 456.10 | 334.75 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 305.47 | 305.93 | 62.66 | 23.73 | 22.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 305.47 | 305.93 | 62.66 | 23.73 | 22.17 |
Effect of Exchange Rate Changes | -0.01 | -0.01 | 0.07 | 0.01 | 0.06 |
Net Change In Cash & Equivalents | 94.92 | 317.88 | 177.01 | 315.54 | 232.54 |
Cash at Beginning of Period | 401.07 | 401.07 | 224.06 | 224.06 | 224.06 |
Cash at End of Period | 495.99 | 718.94 | 401.07 | 539.60 | 456.60 |
Diluted Net EPS | -1.49 | -1.43 | 1.12 | -1.41 | -0.98 |